Inhalable Deuterated DMT Formulations for Longer Therapeutic Action

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing parenteral formulations of DMT and substituted dimethyltryptamines lack improved availability and extended pharmacokinetics for clinically applicable psychedelic drug substances to assist psychotherapy.

Innovation Solution

Formulations comprising a freebase of a deuterium-substituted DMT compound and a biocompatible excipient, which are metabolized more slowly, allowing for a longer lasting therapeutic effect.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If classical psychedelics like DMT are used for therapeutic purposes, then therapeutic effects are achieved, but the duration of action is too short for clinically applicable psychotherapy

Engineering Contradiction:

Improveduration of therapeutic effectVSAvoidmetabolic rate

Core Design Contradiction:

Duration of action of moving objectVSProductivity

Solution Approach 1:

The patent applies isotopic substitution by replacing hydrogen atoms with deuterium atoms in the DMT molecule. This parameter change at the molecular level increases the mass of specific atoms, which slows down metabolic degradation rates through the kinetic isotope effect, thereby extending the duration of therapeutic action from minutes to hours

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates deuterated analogues of DMT that combine the psychoactive properties of DMT with the metabolic stability of deuterated compounds. This composite molecular structure integrates both the therapeutic efficacy of classical psychedelics and the prolonged duration characteristics needed for clinical psychotherapy applications

Inventive Principle:

Principle #40Composite materials

2Reliability

If DMT is administered for therapeutic purposes, then psychiatric disorders can be treated, but improved availability and extended pharmacokinetics are lacking

Engineering Contradiction:

Improvepharmacokinetic profileVSAvoidformulation complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent modifies the chemical parameters of DMT by substituting hydrogen with deuterium at specific positions in the molecular structure. This parameter change fundamentally alters the pharmacokinetic profile, improving reliability of therapeutic delivery while maintaining compatibility with existing formulation techniques

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The deuterium-substituted DMT compounds provide improved availability and prolonged therapeutic effect, suitable for treating psychiatric or neurological disorders.

Implementation Method 1

Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio-analogues, allowing for a longer lasting therapeutic effect

Methodology Applied

Scientific EffectKinetic isotope effect:

Data Source

PatentUS12521370B2Inhalable formulations

Publication Date: 2026.01.13 CYBIN UK LTD

AI summary

The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.